Current and historical daily PE Ratio for Sanofi SA (
) from 2002 to Apr 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Sanofi stock (SNY) PE ratio as of Apr 23 2024 is 20.42.
More Details
Sanofi SA (SNY) PE Ratio (TTM) Chart
Sanofi SA (SNY) PE Ratio (TTM) Historical Data
View and export this data going back to 2002. Start your Free Trial
Total 1213
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Sanofi PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-24 | 20.4 | 2024-02-16 | 19.8 |
| 2024-04-22 | 20.2 | 2024-02-15 | 19.9 |
| 2024-04-19 | 19.8 | 2024-02-14 | 19.6 |
| 2024-04-18 | 19.4 | 2024-02-13 | 19.6 |
| 2024-04-17 | 19.8 | 2024-02-12 | 19.9 |
| 2024-04-16 | 19.6 | 2024-02-09 | 19.9 |
| 2024-04-15 | 19.8 | 2024-02-08 | 19.9 |
| 2024-04-12 | 19.7 | 2024-02-07 | 20.1 |
| 2024-04-11 | 20.0 | 2024-02-06 | 20.1 |
| 2024-04-10 | 20.2 | 2024-02-05 | 20.1 |
| 2024-04-09 | 20.4 | 2024-02-02 | 20.2 |
| 2024-04-08 | 20.2 | 2024-02-01 | 20.7 |
| 2024-04-05 | 20.2 | 2024-01-31 | 21.4 |
| 2024-04-04 | 20.5 | 2024-01-30 | 21.5 |
| 2024-04-03 | 20.5 | 2024-01-29 | 21.5 |
| 2024-04-02 | 20.4 | 2024-01-26 | 21.5 |
| 2024-04-01 | 20.7 | 2024-01-25 | 21.4 |
| 2024-03-28 | 20.8 | 2024-01-24 | 21.4 |
| 2024-03-27 | 21.2 | 2024-01-23 | 21.4 |
| 2024-03-26 | 21.3 | 2024-01-22 | 21.8 |
| 2024-03-25 | 21.2 | 2024-01-19 | 21.9 |
| 2024-03-22 | 20.6 | 2024-01-18 | 22.2 |
| 2024-03-21 | 20.4 | 2024-01-17 | 22.1 |
| 2024-03-20 | 20.7 | 2024-01-16 | 22.1 |
| 2024-03-19 | 20.3 | 2024-01-12 | 22.4 |
| 2024-03-18 | 20.5 | 2024-01-11 | 22.5 |
| 2024-03-15 | 20.7 | 2024-01-10 | 22.4 |
| 2024-03-14 | 20.6 | 2024-01-09 | 22.2 |
| 2024-03-13 | 20.7 | 2024-01-08 | 22.3 |
| 2024-03-12 | 20.8 | 2024-01-05 | 21.9 |
| 2024-03-11 | 20.7 | 2024-01-04 | 21.9 |
| 2024-03-08 | 20.7 | 2024-01-03 | 21.7 |
| 2024-03-07 | 20.6 | 2024-01-02 | 21.4 |
| 2024-03-06 | 20.4 | 2023-12-29 | 21.3 |
| 2024-03-05 | 20.3 | 2023-12-28 | 21.1 |
| 2024-03-04 | 20.2 | 2023-12-27 | 13.6 |
| 2024-03-01 | 20.3 | 2023-12-26 | 13.4 |
| 2024-02-29 | 20.5 | 2023-12-22 | 13.3 |
| 2024-02-28 | 20.6 | 2023-12-21 | 13.3 |
| 2024-02-27 | 20.6 | 2023-12-20 | 13.2 |
| 2024-02-26 | 20.6 | 2023-12-19 | 13.4 |
| 2024-02-23 | 20.9 | 2023-12-18 | 13.2 |
| 2024-02-22 | 20.5 | 2023-12-15 | 13.0 |
| 2024-02-21 | 20.5 | 2023-12-14 | 13.2 |
| 2024-02-20 | 20.1 | 2023-12-13 | 13.2 |
Sanofi SA (SNY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Sanofi SA
NAICS : 325412
SIC : 2834
ISIN : US80105N1054
Share Class Description:
SNY: ADRCompare
Compare
Traded in other countries / regions
SNY.USA0O59.UKSAN.FranceSNW.GermanySNY.Mexico1SAN.ItalySANO.Austria IPO Date
2002-07-01Description
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers